The Translatability Dashboard supports understanding of how toxicity events derived from experimental assays and animal models translate to the clinic.
Bioinfogate is proud to announce the launch of the new OFF-X Translatability Dashboard. The Dashboard supports understanding of how toxicity events derived from experimental assays and animal models translate to the clinic, allowing researchers to prioritize experimental testing and anticipate potential safety issues when designing clinical trials and identify emerging class liabilities.
The translatability dashboard concept has been developed based on the unique and vast array of information in OFF-X, which spans over 14,000 targets of therapeutic interest and almost 800,000 individual alerts manually curated by the Bioinfogate editorial team in the last 5 years. The availability of data from knockout studies, human genetics and pharmacological intervention demonstrate how varying action at the molecular level (e.g. activation, inhibition, inactivation) of the pathway can lead to a benefit for –or in some cases detriment to –patients.
Bioinfogate OFF-X delivers actionable toxicity and safety intelligence to researchers and decision makers in pharmaceutical and healthcare organizations. By delivering critical integrated preclinical toxicity and clinical adverse event intelligence coupled to advanced analytics, Bioinfogate OFF-X allows safety liabilities to be monitored and anticipated across all phases of drug R&D and post-marketing. OFF-X provides integrated information for drugs and targets in all phases of drug R&D, including first-in-class and emerging targets.
The OFF-X Translatability Dashboard can be used in a variety of drug R&D scenarios, including target safety assessments, mechanistic understanding of potential toxicity issues, identifying ways and models that could be used to monitor or assess adverse events, building new panels for off-target assessment, understanding differences in effect between healthy volunteers and diseased patients to support clinical efficacy/safety findings, and analyzing reverse translation from clinical/post-marketing adverse events.
Dr Josep Prous, Jr, Executive Director at Bioinfogate commented: “We are very pleased to add this new functionality in OFF-X and to position the tool as a unique translational safety intelligence portal, from early target discovery to pharmacovigilance needs. This responds to the needs of our customers in pharmaceutical research organizations, regulatory bodies and clinical research organizations who rely on OFF-X as a unique resource in the finding of safer drugs in any therapeutic area of interest.”
Launched in 2016, OFF-X® is used across pharma and biotech organizations, in leading research centers and by regulatory bodies around the world, addressing the need for new approaches to enhance safety assessments that can reduce patient burden and avoid costly failures.
The Bioinfogate OFF-X® portal provides integrated target discovery, non-clinical and clinical adverse event intelligence and pharmacovigilance insights for drugs and targets in all phases of drug R&D and post-marketing.
By delivering critical integrated target discovery, preclinical toxicity, clinical adverse event intelligence and pharmacovigilance insights coupled to advanced analytics, Bioinfogate OFF-X, allows safety liabilities to be monitored and anticipated across all phases of drug R&D and post-marketing. OFF-X is updated daily and more than 4,000 expertly curated alerts are added to the portal each week.
As of March 2021, the portal covers a range of over 15,000 targets and 21,500 drugs & biologics, and is populated with more than 1.1 million expertly curated safety alerts associated to over 10,000 adverse effects. OFF-X® is used across pharma and biotech organizations, in leading research centers and regulatory bodies.
For more information visit targetsafety.info.
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.
Investor Relations Contact
Mark Donohue, Head of Investor Relations
+1 (215) 243 2202
Tabita Seagrave, Head of Global Corporate Communications